SACS and type 2 diabetes mellitus: As human pancreatic islets from T2D donors display a reduced expression of genes impacting oxidative phosphorylation42,43, SACS may be epigenetically targeted in beta cells in a future attempt to restore mitochondrial function and modify insulin secretion.